PTGS2 and skin neoplasm: Other possible pathways for the involvement of RosA in reducing skin cancer development are related to its ability to inhibit the overexpression of cyclooxygenase-2 (COX-2) and other pro-inflammatory products (e.g., prostaglandin E2; PGE2), known as critical mediators of inflammatory response [146,147].